Telix Pharmaceuticals Limited
TLX
Hisse Senetlerindeki Sıralama
#4462
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical... Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
Hisse Fiyatı
$10.30
Piyasa Değeri
$3.50B
Değişim (1 gün)
-0.48%
Değişim (1 yıl)
-6.41%
Ülke
AU
Ticaret Telix Pharmaceuticals Limited (TLX)
Kategori
Healthcare
Telix Pharmaceuticals Limited (TLX) için P/S oranı
October 2026 itibarıyla P/S oranı TTM: 3.90
Telix Pharmaceuticals Limited şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 3.90'dir. 2023 yılının sonunda şirketin P/S oranı 6.40 idi.
Telix Pharmaceuticals Limited için P/S oranı geçmişi 2000 - 2026 arası
Her yılın sonunda P/S oranı
| Yıl | P/S Oranı | Değiştir |
|---|---|---|
| 2026 (TTM) | 3.90 | -62.55% |
| 2024 | 10.41 | 62.57% |
| 2023 | 6.40 | -54.62% |
| 2022 | 14.11 | -95.10% |
| 2021 | 287.93 | 54.34% |
| 2020 | 186.55 | 79.68% |
| 2019 | 103.82 | -84.58% |
| 2018 | 673.26 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Benzer şirketler veya rakipler için P/S oranı
| Şirket | P/S Oranı | P/S Oranı Farkı | Ülke |
|---|---|---|---|
| 10.02 | 157.07% |
US
|
|
| 40.55 | 940.14% |
US
|
|
| 3.96 | 1.60% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 160.25% |
NL
|
